MedWatch

Orexo misses out on millions after losing patent infringement suit against Actavis

Swedish drug group Orexo has lost a US patent infringement suit against the Teva-company Actavis. The CEO considers appealing the ruling but another trial will be expensive.  

Foto: Orexo/PR

The District Court of Delaware, US, has settled a patent dispute between Israeli drug group Teva and Swedish biotech company Orexo.

The court ruled in favor of Teva in the case about one of Orexo's six US patents on the drug Zubsolv for the treatment of opioid dependence.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier